epoxide hydrolase


Also found in: Acronyms, Wikipedia.

epoxide hydrolase

This enzyme name was retired in 2006, as its activity is due to two different enzymes:
• EC 3.3.2.9 (microsomal epoxide hydrolase); and
• EC 3.3.2.10 (soluble epoxide hydrolase).
References in periodicals archive ?
Soluble epoxide hydrolase (50 ng/ml) were mixed with the inhibitors, tanshinone IIA (final concentration 0-10 [micro]M), cryptotanshinone (final concentration 0-100 [micro]M) or salvianolic acid C (final concentration 0-100 [micro]M) and preincubed at 37[degrees]C for 5 min.
Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.
Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies.
Cataboism of epoxy fatty esters by the purified epoxide hydrolase from mouse end human liver.
AR9281, a Soluble Epoxide Hydrolase Inhibitor - Efficacy in a DIO Mouse Model plus Pharmacokinetics and Pharmacodynamics in Mice and Men" (Whitcomb, R, Chen, D, Wang, J, Anandan, S-K, Gless, R and Webb, H).
In terms of detoxification systems, Table 1 shows that epoxide hydrolase is active at birth but apparently only at 50% of adult function.
Association between lung cancer and microsomal epoxide hydrolase genotypes.
In a microarray study using ovaries from animals treated with DEHP in vivo, a select number of altered genes suggest an oxidative stress response, including the aryl hydrocarbon receptor, CYP1B 1, and epoxide hydrolase (Lovekamp-Swan.
a privately-held biotechnology company developing first-in-class soluble epoxide hydrolase (s-EH) inhibitors, today announced that it has closed the final tranche of its Series A financing.
Substituted ureas and carbamates are mechanistic inhibitors of the soluble epoxide hydrolase (sEH).
a privately-held biopharmaceutical company developing first-in-class soluble epoxide hydrolase (s-EH) inhibitors, today named D.
Arete Therapeutics is uniquely positioned to develop its pipeline of novel soluble epoxide hydrolase inhibitors for multiple disease indications and I look forward to applying my experience to build on the strong foundation and take the company to the next level of strategic and scientific excellence," said Dr.